keyword
MENU ▼
Read by QxMD icon Read
search

Nivolumab

keyword
https://www.readbyqxmd.com/read/29145556/combination-ipilimumab-and-nivolumab-for-metastatic-melanoma-associated-with-ciliochoroidal-effusion-and-exudative-retinal-detachment
#1
Edmund Tsui, Assumpta Madu, Irina Belinsky, Lawrence A Yannuzzi, K Bailey Freund, Yasha S Modi
No abstract text is available yet for this article.
November 16, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/29145036/liver-immunotolerance-and-hepatocellular-carcinoma-patho-physiological-mechanisms-and-therapeutic-perspectives
#2
REVIEW
Gaël S Roth, Thomas Decaens
At the moment of the diagnosis of hepatocellular carcinoma (HCC), 70% of patients have only access to palliative treatments, with very few therapeutic options. Liver immunology is very specific, and liver immunotolerance is particularly developed because of the constant and massive influx of antigens. Deregulation of hepatic immunotolerance is implicated in chronic liver diseases development and particularly in liver carcinogenesis. For these reasons, HCC may be an excellent candidate for anticancer immunotherapies such as immune checkpoint inhibitors targeting CTLA-4 and PD-L1/PD-1...
November 13, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29143108/immune-checkpoint-inhibitor-colitis-the-flip-side-of-the-wonder-drugs
#3
Naziheh Assarzadegan, Elizabeth Montgomery, Robert A Anders
Immune checkpoint inhibitors block the co-inhibitory receptors on T cells to activate their cytotoxic immune function and are rapidly being explored for the treatment of various advanced-stage malignancies. These novel drugs have already significantly increased survival rates. The first available immune checkpoint inhibitors were cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors (such as ipilimumab), followed by programmed cell death protein 1 (PD-1) and programmed cell death protein ligand 1 (PD-L1) inhibitors (such as pembrolizumab and nivolumab)...
November 15, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/29138342/immunotherapy-of-hepatocellular-carcinoma-facts-and-hopes
#4
Mercedes Iñarrairaegui, Ignacio Melero, Bruno Sangro
Treatment of patients with hepatocellular carcinoma in the advanced stage remains a great challenge, with very few drugs approved. After decades of failures of immune therapies, immune checkpoint inhibitors have emerged as potentially effective treatments for patients with hepatocellular carcinoma in the advanced stage. Immune checkpoints, including human cancer, cytotoxic T-lymphocyte protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), are surface proteins expressed in a variety of immune cells, and mostly provide immunosuppressive signals...
November 14, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29137370/comparative-efficacy-and-safety-of-immune-checkpoint-inhibitor-related-therapies-for-advanced-melanoma-a-bayesian-network-analysis
#5
Xin Li, Junpeng Wang, Yun Yao, Lei Yang, Zhiqin Li, Cheng Yu, Peiyan Zhao, Yongli Yu, Liying Wang
Objectives: We aimed to compare and rank the effects of 9 immune checkpoint inhibitor-related therapies for treating advanced melanoma. Methods: We searched Pubmed, Cochrane databases, Web of Science, and ClinicalTrials.gov for randomized controlled trials of the immune checkpoint inhibitor-related treatments for advanced melanoma. Analysis was done on a Bayesian framework. Results: Twelve trials including 5413 patients were identified. Ipilimumab plus nivolumab, nivolumab, and pembrolizumab were significantly more efficacious for progression-free survival (PFS) than ipilimumab (hazard ratio [HR], 0...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29134564/seom-clinical-guideline-for-treatment-of-kidney-cancer-2017
#6
E Gallardo, M J Méndez-Vidal, J L Pérez-Gracia, J M Sepúlveda-Sánchez, M Campayo, I Chirivella-González, X García-Del-Muro, A González-Del-Alba, E Grande, C Suárez
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma...
November 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29133768/severe-pneumonitis-after-nivolumab-treatment-accompanied-by-acute-pulmonary-embolism-in-a-patient-with-lung-adenocarcinoma
#7
Ji-Ping Liao, Li-Gong Nie, Cheng-Li Que, Xiang-Dong Mu
No abstract text is available yet for this article.
November 20, 2017: Chinese Medical Journal
https://www.readbyqxmd.com/read/29133121/analysis-of-early-death-in-japanese-patients-with-advanced-non-small-cell-lung-cancer-treated-with-nivolumab
#8
Takako Inoue, Motohiro Tamiya, Akihiro Tamiya, Kenji Nakahama, Yoshihiko Taniguchi, Takayuki Shiroyama, Shin-Ichi Isa, Kazumi Nishino, Toru Kumagai, Kei Kunimasa, Madoka Kimura, Hidekazu Suzuki, Tomonori Hirashima, Shinji Atagi, Fumio Imamura
BACKGROUND: The increased risk for early death owing to anti-programmed cell death 1 inhibitors is a major disadvantage that requires special management. We evaluated the frequency, causes, and risk factors of early death during nivolumab treatment for non-small cell lung cancer (NSCLC) in a Japanese clinical setting. PATIENTS AND METHODS: The medical records of patients with NSCLC who started receiving nivolumab between December 17, 2015 and July 31, 2016 in 3 Japanese institutes were collected...
October 13, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29131510/pulmonary-pleomorphic-carcinoma-with-few-pd-1-positive-immune-cells-and-regulatory-t-cells-that-showed-a-complete-response-to-nivolumab
#9
Kazuaki Okamura, Yuichi Fukuda, Hiroshi Soda, Daiki Ogawara, Keisuke Iwasaki, Shinichiro Fuchi, Takayuki Suyama, Masataka Yoshida, Tatsuhiko Harada, Minoru Fukuda, Hiroshi Mukae
Pulmonary pleomorphic carcinoma has been shown to respond remarkably to PD-1 inhibitors; however, the biomarkers for this therapy have not been fully proven. We report a case of pulmonary pleomorphic carcinoma with overexpressed PD-L1, in which a complete response to nivolumab was sustained for >14 months. Immunohistochemical analysis revealed few PD-1(+) immune cells and regulatory T cells in the tumor, in addition to predominant infiltration of CD8(+) cells and macrophages. Our findings suggest that the presence of a small number of PD-1(+) immune cells and regulatory T cells should be investigated as candidate therapeutic biomarkers...
November 13, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/29131040/adverse-reactions-to-biologics-melanoma-ipilimumab-nivolumab-pembrolizumab
#10
Shelley Ji Eun Hwang, Pablo Fernández-Peñas
With increasing use of immunotherapies such as anti-cytotoxic T cell lymphocyte antigen-4 and anti-programmed cell death 1 antibodies, various skin toxicities have emerged. Severity of skin toxicities varies from mild lichenoid reaction to severe toxic epidermal necrolysis. Appropriate diagnosis and management of these skin toxicities are essential for optimal patient care and to avoid unnecessary cessation of anti-cancer therapies. This review summarises a wide range of cutaneous manifestations associated with immunotherapy usage in patients with metastatic melanoma...
2018: Current Problems in Dermatology
https://www.readbyqxmd.com/read/29130342/nivolumab-in-recurrent-metastatic-head-and-neck-cancers
#11
Andy Karabajakian, Thibaut Reverdy, Max Gau, Jérôme Fayette
Head and neck cancer is an immunosuppressive disease, with a high proportion expressing PD-L1. Until recently, options were lacking in second line. Prognosis is poor especially for patients who progress during chemotherapy with survival often inferior to 6 months. Nivolumab is the only anti-PD1 agent to prolong survival in the second-line setting and is now the standard option since the CheckMate-141 trial. Treatment is generally well tolerated, patients seem to have a better quality of life when compared with chemotherapy...
November 13, 2017: Future Oncology
https://www.readbyqxmd.com/read/29129758/impact-of-nivolumab-versus-docetaxel-on-health-related-quality-of-life-and-symptoms-in-patients-with-advanced-squamous-non-small-cell-lung-cancer-results-from-the-checkmate-017-study
#12
Martin Reck, Fiona Taylor, John R Penrod, Michael DeRosa, Laura Morrissey, Homa Dastani, Lucinda Orsini, Richard J Gralla
INTRODUCTION: In the phase III CheckMate 017 study, nivolumab prolonged overall survival versus docetaxel in previously treated patients with advanced squamous non-small cell lung cancer (NSCLC). Study objectives included health-related quality of life (HRQoL) and symptom assessments. METHODS: Patients serially completed Lung Cancer Symptom Scale (LCSS) and European Quality of Life Five Dimensions (EQ-5D) questionnaires. The LCSS average symptom burden index (ASBI; mean score for six lung cancer-specific symptoms; range, 0-100), LCSS 3-item global index, EQ-5D utility index, and EQ-5D visual analog scale scores were analyzed...
November 9, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29126352/fatal-myocarditis-and-rhabdomyolysis-induced-by-nivolumab-during-the-treatment-of-type-b3-thymoma
#13
Qiang Chen, Dang-Sheng Huang, Li-Wei Zhang, Yuan-Qing Li, Hong-Wei Wang, Hong-Bin Liu
Immune checkpoint inhibitors including programmed death-1 inhibitors are promising agents for many types of malignancies; however, it is still an off-label choice for type B3 thymoma. We reported for the first time a patient with type B3 thymoma developed fatal myocarditis and rhabdomyolysis after one dose of nivolumab administration. The results from myocardial and muscle biopsies revealed extensive myocyte damage, T-lymphocytic infiltration and strongly expression of PD-L1 which confirmed the nivolumab-related immune-related adverse events (irAEs)...
November 10, 2017: Clinical Toxicology
https://www.readbyqxmd.com/read/29126314/cost-effectiveness-analysis-of-nivolumab-for-treatment-of-platinum-resistant-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck
#14
Kathryn R Tringale, Kate T Carroll, Kaveh Zakeri, Assuntina G Sacco, Linda Barnachea, James D Murphy
Background: The CheckMate 141 trial found that nivolumab improved survival for patients with recurrent or metastatic head and neck cancer (HNC). Despite the improved survival, nivolumab is much more expensive than standard therapies. This study assesses the cost-effectiveness of nivolumab for the treatment of HNC. Methods: We constructed a Markov model to simulate treatment with nivolumab or standard single-agent therapy for patients with recurrent or metastatic platinum-refractory HNC...
November 3, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29125905/arthritis-after-cancer-immunotherapy-symptom-duration-and-treatment-response
#15
Melanie H Smith, Anne R Bass
OBJECTIVE: Musculoskeletal manifestations of immune related adverse events (irAEs) after checkpoint inhibitor immunotherapy for cancer remain incompletely characterized and poorly understood. A recently published case series suggested that immunotherapy-induced arthritis is an aggressive process requiring high dose corticosteroids. METHODS: This was a retrospective chart review of all patients with musculoskeletal irAEs first seen by one of the authors between 2014 and 2016...
November 10, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/29124007/immunotherapy-shock-with-vitiligo-due-to-nivolumab-administration-as-third-line-therapy-in-lung-adenocarcinoma
#16
Paul Zarogoulidis, Haidong Huang, Theodora Tsiouda, Chrysa Sardeli, Georgia Trakada, Lemonia Veletza, Anastasios Kallianos, Christoforos Kosmidis, Aggeliki Rapti, Liana Papaemmanouil, Dimitrios Hatzibougias, Dimitrios Drougas, Chong Bai, Wolfgang Hohenforst-Schmidt
Non-small cell lung cancer is still diagnosed at late stage due to the lack of early symptoms and methods of diagnostic prevention. In the past ten years several targeted therapies have been introduced or explored. Tyrosine kinase inhibitors and immunotherapy are currently considered the most effective and safe therapies in comparison to the non-specific cytotoxic agents. Regarding tyrosine kinase inhibitors the adverse effects have been fully explored, however; on the other hand for immunotherapy there are still several issues to be clarified...
2017: Respiratory Medicine Case Reports
https://www.readbyqxmd.com/read/29123955/incidence-of-immune-checkpoint-inhibitor-related-colitis-in-solid-tumor-patients-a-systematic-review-and-meta-analysis
#17
Daniel Y Wang, Fei Ye, Shilin Zhao, Douglas B Johnson
Background: With the rising use of immune checkpoint inhibitors (ICI) across varying tumors types, immune-related colitis is an increasingly encountered, serious adverse event requiring appropriate management. The incidence across ICI treatment regimens and tumor types is unclear. Objective: To characterize the incidence of immune-related colitis among various ICI regimens and tumor types. Methods: Thirty-four original studies of prospective ICI trials were identified based on a PubMed search completed on November 1st, 2016...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/29123953/pd-1-blockade-augments-anti-neuroblastoma-immune-response-induced-by-anti-gd2-antibody-ch14-18-cho
#18
Nikolai Siebert, Maxi Zumpe, Madlen Jüttner, Sascha Troschke-Meurer, Holger N Lode
Immunotherapy with anti-GD2 antibody (Ab) ch14.18/CHO is effective for treatment of high-risk neuroblastoma (NB) patients and is mainly based on GD2-specific Ab-dependent cellular cytotoxicity (ADCC). Strategies to further enhance the efficacy are important and currently explored in prospective clinical trials randomizing ch14.18/CHO ± IL-2. Recently, expression of programmed death 1 (PD-1) inhibitory receptor by effector cells and its ligand (PD-L1) by tumor cells has been shown. Here, we report for the first time effects of PD-1 blockade on ch14...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/29120911/immunotherapy-for-kidney-cancer-status-quo-and-the-future
#19
Jens Bedke, Viktoria Stühler, Arnulf Stenzl, Bernhard Brehmer
PURPOSE OF REVIEW: The treatment landscape in advanced and metastatic renal cell carcinoma (RCC) is moving from the inhibition of tyrosine kinases (TKI) and the mammalian target of rapamycin (mTOR) inhibitors to specific immunooncology agents like immune checkpoint inhibitors (ICI). The review focus on the recent immunooncology developments and available trial results within the last 12 months. RECENT FINDINGS: ICI as monotherapy (nivolumab) or immunooncology and immunooncology combinations (nivolumab and ipilimumab) demonstrated positive results on prolonged overall survival in phase III trials...
November 7, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/29119852/platelet-related-indices-in-patients-with-lung-cancer-with-nivolumab
#20
Shosaku Nomura, Takashi Yokoi, Takayasu Kurata
No abstract text is available yet for this article.
November 9, 2017: Platelets
keyword
keyword
9969
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"